Cargando…
Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis
BACKGROUND: Glioblastoma Multiforme (GBM) is one of the most aggressive primary brain tumors and is associated with a dismal prognosis. The median survival after the primary diagnosis remains poor, even after multimodal treatment approaches. However, a few patients have been reported to have long te...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502257/ https://www.ncbi.nlm.nih.gov/pubmed/22553975 http://dx.doi.org/10.1186/1477-7819-10-75 |
_version_ | 1782250298245382144 |
---|---|
author | Thumma, Sudheer R Fairbanks, Robert K Lamoreaux, Wayne T Mackay, Alexander R Demakas, John J Cooke, Barton S Elaimy, Ameer L Hanson, Peter W Lee, Christopher M |
author_facet | Thumma, Sudheer R Fairbanks, Robert K Lamoreaux, Wayne T Mackay, Alexander R Demakas, John J Cooke, Barton S Elaimy, Ameer L Hanson, Peter W Lee, Christopher M |
author_sort | Thumma, Sudheer R |
collection | PubMed |
description | BACKGROUND: Glioblastoma Multiforme (GBM) is one of the most aggressive primary brain tumors and is associated with a dismal prognosis. The median survival after the primary diagnosis remains poor, even after multimodal treatment approaches. However, a few patients have been reported to have long term survival greater than three years. A number of studies have attempted to define factors capable of predicting long term outcomes in specific patient groups. This article reports the outcomes of a very large group of patients diagnosed with GBM, and analyzes specific prognostic factors known to influence survival in these patients. METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) database of the US National Cancer Institute (NCI) to investigate various patient-related and treatment- related factors that could influence the long term survival in patients diagnosed with glioblastoma. A total of 34,664 patients aged 20 years or older with a diagnosis of GBM during the years 1973 to 2008 were studied. Overall survival outcomes were examined with Kaplan-Meier survival analysis and Cox hazard models. RESULTS: Asian/Pacific Islanders had a better survival compared to the white population (P = <0.001). Patients diagnosed with GBM during the years 2000 to 2008 had a superior survival rate when compared with earlier decades (P = <0 .001). Statistically significant improvements in overall survival were also found for patients who received surgical resections, and adjuvant radiation treatment versus no radiation (P-values <0.001). Young age was also found to be highly predictive of improved overall survival rates when separated into age groups as well as when studied as a continuous variable. CONCLUSIONS: Clinical pretreatment and treatment factors, including young age at diagnosis, Asian/Pacific Islander ethnicity, recent year of diagnosis, surgical resection and the use of adjuvant radiation therapy favorably influence survival in patients diagnosed with glioblastoma. TRIAL REGISTRATION: All data were obtained from the United States Surveillance Epidemiology and End Results (SEER) database. |
format | Online Article Text |
id | pubmed-3502257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35022572012-11-21 Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis Thumma, Sudheer R Fairbanks, Robert K Lamoreaux, Wayne T Mackay, Alexander R Demakas, John J Cooke, Barton S Elaimy, Ameer L Hanson, Peter W Lee, Christopher M World J Surg Oncol Research BACKGROUND: Glioblastoma Multiforme (GBM) is one of the most aggressive primary brain tumors and is associated with a dismal prognosis. The median survival after the primary diagnosis remains poor, even after multimodal treatment approaches. However, a few patients have been reported to have long term survival greater than three years. A number of studies have attempted to define factors capable of predicting long term outcomes in specific patient groups. This article reports the outcomes of a very large group of patients diagnosed with GBM, and analyzes specific prognostic factors known to influence survival in these patients. METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) database of the US National Cancer Institute (NCI) to investigate various patient-related and treatment- related factors that could influence the long term survival in patients diagnosed with glioblastoma. A total of 34,664 patients aged 20 years or older with a diagnosis of GBM during the years 1973 to 2008 were studied. Overall survival outcomes were examined with Kaplan-Meier survival analysis and Cox hazard models. RESULTS: Asian/Pacific Islanders had a better survival compared to the white population (P = <0.001). Patients diagnosed with GBM during the years 2000 to 2008 had a superior survival rate when compared with earlier decades (P = <0 .001). Statistically significant improvements in overall survival were also found for patients who received surgical resections, and adjuvant radiation treatment versus no radiation (P-values <0.001). Young age was also found to be highly predictive of improved overall survival rates when separated into age groups as well as when studied as a continuous variable. CONCLUSIONS: Clinical pretreatment and treatment factors, including young age at diagnosis, Asian/Pacific Islander ethnicity, recent year of diagnosis, surgical resection and the use of adjuvant radiation therapy favorably influence survival in patients diagnosed with glioblastoma. TRIAL REGISTRATION: All data were obtained from the United States Surveillance Epidemiology and End Results (SEER) database. BioMed Central 2012-05-03 /pmc/articles/PMC3502257/ /pubmed/22553975 http://dx.doi.org/10.1186/1477-7819-10-75 Text en Copyright ©2012 Thumma et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Thumma, Sudheer R Fairbanks, Robert K Lamoreaux, Wayne T Mackay, Alexander R Demakas, John J Cooke, Barton S Elaimy, Ameer L Hanson, Peter W Lee, Christopher M Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis |
title | Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis |
title_full | Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis |
title_fullStr | Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis |
title_full_unstemmed | Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis |
title_short | Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis |
title_sort | effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a surveillance epidemiology and end results (seer) population analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502257/ https://www.ncbi.nlm.nih.gov/pubmed/22553975 http://dx.doi.org/10.1186/1477-7819-10-75 |
work_keys_str_mv | AT thummasudheerr effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT fairbanksrobertk effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT lamoreauxwaynet effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT mackayalexanderr effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT demakasjohnj effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT cookebartons effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT elaimyameerl effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT hansonpeterw effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis AT leechristopherm effectofpretreatmentclinicalfactorsonoverallsurvivalinglioblastomamultiformeasurveillanceepidemiologyandendresultsseerpopulationanalysis |